In this CE Concepts live symposium, expert faculty will incorporate patient-reported pain and quality-of-life data into treatment decision-making for patients with NF1-associated plexiform neurofibromas. Learners will be shown how to assess evidence‑based strategies for integrating MEK inhibitor therapy with surgery in the multidisciplinary management of patients with NF1‑PNs. Faculty will discuss structured, evidence-based strategies to anticipate, monitor, and manage MEK inhibitor-related toxicities in patients with NF1-PNs while maintaining dose intensity and minimizing treatment discontinuation across pediatric and adult care settings.
In this CE Concepts live symposium, expert faculty will review the latest clinical evidence for integrating FRα testing into treatment decision-making as well as practical strategies for selecting and sequencing FRα-targeted ADCs, including anticipating and managing toxicities, to deliver personalized, multidisciplinary care with greater confidence in the rapidly evolving PROC treatment landscape.
In this CE Concepts live symposium, faculty will apply NF1 diagnostic and oncologic monitoring guidelines to support early recognition of NF1-PNs in pediatric patients. Learners will be shown how to incorporate MEK inhibitors in the management of NF1-PNs in pediatric patients within care pathways that extend into adult-focused settings through evidence-based monitoring and safety support. Faculty will model the application of interprofessional care coordination and continuity planning strategies in clinical practice to support consistent management of patients with NF1 across pediatric and adult care settings.
In this CE Concepts recorded symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.
